Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $221.57 | 2 | 50.8% |
| Education | $214.95 | 5 | 49.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $214.95 | 5 | $0 (2023) |
| Theravance Biopharma, Inc. | $118.30 | 1 | $0 (2018) |
| 3B Medical, Inc. | $103.27 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $183.26 | 2 | 3B Medical, Inc. ($103.27) |
| 2021 | $69.98 | 2 | Astellas Pharma US Inc ($69.98) |
| 2018 | $158.29 | 2 | Theravance Biopharma, Inc. ($118.30) |
| 2017 | $24.99 | 1 | Astellas Pharma US Inc ($24.99) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2023 | 3B Medical, Inc. | LUNA (Device) | Food and Beverage | Cash or cash equivalent | $103.27 | General |
| Category: VENTILATOR, NON-CONTINUOUS (RESPIRATOR) | ||||||
| 09/19/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 09/02/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $39.99 | General |
| 08/16/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $29.99 | General |
| 11/01/2018 | Theravance Biopharma, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $118.30 | General |
| Category: Infectious Disease | ||||||
| 07/25/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $39.99 | General |
| 05/04/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $24.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,059 | 92,203 | $1.2M | $303,111 |
| 2022 | 19 | 1,982 | 9,316 | $1.1M | $321,452 |
| 2021 | 22 | 2,541 | 220,557 | $1.9M | $478,052 |
| 2020 | 20 | 2,346 | 146,599 | $1.6M | $459,432 |
All Medicare Procedures & Services
90 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 767 | 1,160 | $342,200 | $110,948 | 32.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 668 | 1,160 | $307,400 | $73,624 | 24.0% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2023 | 15 | 4,500 | $139,500 | $53,235 | 38.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 81 | 367 | $82,575 | $18,161 | 22.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 54 | 54 | $20,250 | $7,568 | 37.4% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 45 | 57 | $14,250 | $6,996 | 49.1% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 57 | 80 | $13,600 | $6,832 | 50.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 61 | 84 | $22,907 | $4,471 | 19.5% |
| 96521 | Refilling and maintenance of portable pump | Office | 2023 | 17 | 35 | $13,125 | $3,411 | 26.0% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 24 | 82,350 | $99,325 | $2,856 | 2.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 19 | $10,341 | $2,713 | 26.2% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 27 | 250 | $19,375 | $2,676 | 13.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 12 | 105 | $9,975 | $2,350 | 23.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 16 | 16 | $8,104 | $1,727 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 13 | $4,991 | $1,322 | 26.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 16 | 17 | $6,526 | $1,262 | 19.3% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 20 | 20 | $1,700 | $823.60 | 48.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 16 | 16 | $3,600 | $648.00 | 18.0% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 23 | 1,248 | $43,680 | $497.28 | 1.1% |
| 11000 | Removal of inflamed or infected skin, up to 10% of body surface | Facility | 2023 | 18 | 18 | $1,800 | $394.92 | 21.9% |
| J0692 | Injection, cefepime hydrochloride, 500 mg | Office | 2023 | 13 | 254 | $9,720 | $250.89 | 2.6% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 50 | 350 | $5,250 | $178.14 | 3.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 17 | 18 | $360.00 | $151.20 | 42.0% |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | Office | 2023 | 12 | 12 | $180.00 | $15.79 | 8.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 545 | 579 | $217,125 | $92,650 | 42.7% |
About Dr. Michael Milam, MD
Dr. Michael Milam, MD is a Infectious Disease healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982701421.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Milam, MD has received a total of $436.52 in payments from pharmaceutical and medical device companies, with $183.26 received in 2023. These payments were reported across 7 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($221.57).
As a Medicare-enrolled provider, Milam has provided services to 8,928 Medicare beneficiaries, totaling 468,675 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 90 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Sarasota, FL
- Active Since 09/19/2006
- Last Updated 10/14/2019
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1982701421
Products in Payments
- VIBATIV (Drug) $118.30
- LUNA (Device) $103.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Sarasota
Dr. Lavinia Suciu, M.d, M.D
Infectious Disease — Payments: $6,987
Andrew Krinsky, Md, MD
Infectious Disease — Payments: $6,044
Manuel Gordillo, Md, MD
Infectious Disease — Payments: $3,558
Rishi Bhattacharyya, Md, MD
Infectious Disease — Payments: $2,529
Natan Kraitman, M.d, M.D
Infectious Disease — Payments: $1,877
Sudha Tallapragada, Md, MD
Infectious Disease — Payments: $1,461